{"component": "contracts", "props": {"contracts": [{"intro": "This is a Third Amendment to Lease dated as of May 16, 2022 by and between Bulfinch Square Limited Partnership, a Massachusetts limited partnership (\u201cLandlord\u201d) and Leap Therapeutics, Inc., a Delaware corporation (\u201cTenant\u201d).", "id": "21vFXW4m61m", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000110465922089656/lptx-20220630xex10d1.htm", "category_name": "Lease", "company_name": "Leap Therapeutics, Inc.", "created": "August 12th, 2022", "published": true, "pretty": null, "uri": "/contracts/21vFXW4m61m", "title": "THIRD AMENDMENT TO LEASE", "group_id": "21vFXW4m61m", "group_samples": [{"label": "Lease (Leap Therapeutics, Inc.)", "uri": "/contracts/21vFXW4m61m", "published": true}], "group_size": 1, "tags": [{"name": "Lease", "type": "category", "uri": "/contracts/tagged/lease"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This RESTRICTED STOCK UNIT AGREEMENT (the \u201cAgreement\u201d), dated as of [\u00b7] (the \u201cDate of Grant\u201d), is delivered by Leap Therapeutics, Inc. (the \u201cCompany\u201d) to [\u00b7] (the \u201cParticipant\u201d).", "id": "2OzgAZO01qO", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000110465919034806/a19-11182_1ex99d2.htm", "category_name": "Restricted Stock Unit Agreement", "company_name": "Leap Therapeutics, Inc.", "created": "June 11th, 2019", "published": true, "pretty": null, "uri": "/contracts/2OzgAZO01qO", "title": "LEAP THERAPEUTICS, INC. 2016 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT", "group_id": "2OzgAZO01qO", "group_samples": [{"label": "Restricted Stock Unit Agreement (Leap Therapeutics, Inc.)", "uri": "/contracts/2OzgAZO01qO", "published": true}], "group_size": 1, "tags": [{"name": "Restricted Stock Unit Agreement", "type": "category", "uri": "/contracts/tagged/restricted-stock-unit-agreement"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "This Agreement is made in connection with: (a) that certain Securities Purchase Agreement, dated as of the date hereof, among the Company and each Purchaser identified on the signature pages thereto, pursuant to which each such Purchasers will be issued securities of the Company in exchange for cash consideration pursuant to the terms thereof (the \u201cPurchase Agreement\u201d); and (b) that certain Lead Investor Agreement, dated on or about the date hereof, between the Company and the lead investor identified on the signature page thereto (the \u201cLead Investor\u201d).", "id": "3iAg0REOuF0", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000110465925098082/tm2528058d2_ex10-2.htm", "category_name": "Registration Rights Agreement", "company_name": "Leap Therapeutics, Inc.", "created": "October 9th, 2025", "published": true, "pretty": null, "uri": "/contracts/3iAg0REOuF0", "title": "REGISTRATION RIGHTS AGREEMENT", "group_id": "3iAg0REOuF0", "group_samples": [{"label": "Registration Rights Agreement (Leap Therapeutics, Inc.)", "uri": "/contracts/3iAg0REOuF0", "published": true}], "group_size": 1, "tags": [{"name": "Registration Rights Agreement", "type": "category", "uri": "/contracts/tagged/registration-rights-agreement"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This WAIVER AND MODIFICATION AGREEMENT (this \u201cAgreement\u201d) is made and entered into as of November 19, 2025, by and between Cypherpunk Technologies Inc. (f/k/a Leap Therapeutics, Inc.), a Delaware corporation (the \u201cCorporation\u201d), and Winklevoss Treasury Investments, LLC (the \u201cHolder\u201d). All capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in that certain Warrant to Purchase Common Stock (Warrant No. 2025 PIPE \u2013 CSW \u2013 1) issued on October 8, 2025 by the Corporation to the Holder (the \u201cWarrant\u201d).", "id": "5DpoQV0iMs8", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000110465925114435/tm2531822d1_ex4-1.htm", "category_name": "Waiver and Modification Agreement", "company_name": "Cypherpunk Technologies Inc.", "created": "November 20th, 2025", "published": true, "pretty": null, "uri": "/contracts/5DpoQV0iMs8", "title": "CYPHERPUNK TECHNOLOGIES INC.", "group_id": "5DpoQV0iMs8", "group_samples": [{"label": "Waiver and Modification Agreement (Cypherpunk Technologies Inc.)", "uri": "/contracts/5DpoQV0iMs8", "published": true}], "group_size": 1, "tags": [{"name": "Waiver and Modification Agreement", "type": "category", "uri": "/contracts/tagged/waiver-and-modification-agreement"}, {"name": "Cypherpunk Technologies Inc.", "type": "company", "uri": "/company/1509745/cypherpunk-technologies-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Registration Rights Agreement (this \u201cAgreement\u201d) is made as of January 17, 2023, by and among Leap Therapeutics, Inc., a Delaware corporation (the \u201cCompany\u201d), and those persons that (i) as of the date of this Agreement become or have become entitled to receive Registrable Securities (as defined in Section 1 below) pursuant to, and in accordance with, the Merger Agreement (as defined below) and (ii) become parties to this Agreement by executing and delivering a counterpart signature page to this Agreement on the date of this Agreement or on any date thereafter (collectively, the \u201cHolders\u201d). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.", "id": "5zCVs8HQzcF", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000110465923005803/tm233885d1_ex10-3.htm", "category_name": "Registration Rights Agreement", "company_name": "Leap Therapeutics, Inc.", "created": "January 23rd, 2023", "published": true, "pretty": null, "uri": "/contracts/5zCVs8HQzcF", "title": "REGISTRATION RIGHTS AGREEMENT", "group_id": "5zCVs8HQzcF", "group_samples": [{"label": "Registration Rights Agreement (Leap Therapeutics, Inc.)", "uri": "/contracts/5zCVs8HQzcF", "published": true}], "group_size": 1, "tags": [{"name": "Registration Rights Agreement", "type": "category", "uri": "/contracts/tagged/registration-rights-agreement"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "This is a Fourth Amendment to Lease dated as of January 3, 2024 by and between Bulfinch Square Limited Partnership, a Massachusetts limited partnership (\u201cLandlord\u201d) and Leap Therapeutics, Inc., a Delaware corporation (\u201cTenant\u201d).", "id": "6B2w3E6odpd", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000141057824000748/lptx-20240331xex10d1.htm", "category_name": "Lease", "company_name": "Leap Therapeutics, Inc.", "created": "May 13th, 2024", "published": true, "pretty": null, "uri": "/contracts/6B2w3E6odpd", "title": "FOURTH AMENDMENT TO LEASE", "group_id": "6B2w3E6odpd", "group_samples": [{"label": "Lease (Leap Therapeutics, Inc.)", "uri": "/contracts/6B2w3E6odpd", "published": true}], "group_size": 1, "tags": [{"name": "Lease", "type": "category", "uri": "/contracts/tagged/lease"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Second Amendment (the \u201cAmendment\u201d) to Executive Employment Agreement is made and entered into as of this 3rd day of April, 2023 (the \u201cAmendment Date\u201d), by and between Leap Therapeutics, Inc., a Delaware corporation (the \u201cCompany\u201d), and Cynthia Sirard (hereinafter, the \u201cExecutive\u201d).", "id": "6OMACA4M6qj", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000110465923043095/tm2312108d1_ex10-1.htm", "category_name": "Executive Employment Agreement", "company_name": "Leap Therapeutics, Inc.", "created": "April 7th, 2023", "published": true, "pretty": null, "uri": "/contracts/6OMACA4M6qj", "title": "SECOND AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT", "group_id": "6OMACA4M6qj", "group_samples": [{"label": "Executive Employment Agreement (Leap Therapeutics, Inc.)", "uri": "/contracts/6OMACA4M6qj", "published": true}], "group_size": 1, "tags": [{"name": "Executive Employment Agreement", "type": "category", "uri": "/contracts/tagged/executive-employment-agreement"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "This First Amendment (the \u201cAmendment\u201d) to Executive Employment Agreement is made and entered into as of this _20_ day of April, 2021 (the \u201cAmendment Date\u201d), by and between Leap Therapeutics, Inc., a Delaware corporation (the \u201cCompany\u201d), and John Mark O\u2019Mahony (hereinafter, the \u201cExecutive\u201d).", "id": "72Onf5x8ooi", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000110465921104593/lptx-20210630xex10d2.htm", "category_name": "Executive Employment Agreement", "company_name": "Leap Therapeutics, Inc.", "created": "August 13th, 2021", "published": true, "pretty": null, "uri": "/contracts/72Onf5x8ooi", "title": "FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT", "group_id": "72Onf5x8ooi", "group_samples": [{"label": "Executive Employment Agreement (Leap Therapeutics, Inc.)", "uri": "/contracts/72Onf5x8ooi", "published": true}], "group_size": 1, "tags": [{"name": "Executive Employment Agreement", "type": "category", "uri": "/contracts/tagged/executive-employment-agreement"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "This STRATEGIC PARTNERSHIP AND LICENSE AGREEMENT (this \u201cAgreement\u201d) is made as of August 13, 2021 (the \u201cEffective Date\u201d), by and between NOVAROCK BIOTHERAPEUTICS LTD., a Delaware corporation (\u201cNovaRock\u201d), having a place of business at 801 Charles Ewing Blvd, Ewing, NJ 08628, USA, and FLAME BIOSCIENCES, INC., a Delaware corporation (\u201cFlame\u201d), having a place of business at 280 Union Square Drive, New Hope, PA 18938. NovaRock and Flame are referred to in this Agreement individually as a \u201cParty\u201d and collectively as the \u201cParties.\u201d", "id": "796HC7se1Vk", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000110465923060153/lptx-20230331xex10d1.htm", "category_name": "Strategic Partnership and License Agreement", "company_name": "Leap Therapeutics, Inc.", "created": "May 15th, 2023", "published": true, "pretty": null, "uri": "/contracts/796HC7se1Vk", "title": "STRATEGIC PARTNERSHIP AND LICENSE AGREEMENT", "group_id": "796HC7se1Vk", "group_samples": [{"label": "Strategic Partnership and License Agreement (Leap Therapeutics, Inc.)", "uri": "/contracts/796HC7se1Vk", "published": true}], "group_size": 1, "tags": [{"name": "Strategic Partnership and License Agreement", "type": "category", "uri": "/contracts/tagged/strategic-partnership-and-license-agreement"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This First Amendment to Lease (this \u201cAmendment\u201d) is made as of January 4, 2016 by and between Bulfinch Square Limited Partnership, a Massachusetts limited partnership (\u201cLandlord\u201d), and Healthcare Ventures LLC, a Delaware limited liability company (\u201cTenant\u201d).", "id": "7jhEwTJL1PY", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000104746917002262/a2231451zex-10_28.htm", "category_name": "Lease", "company_name": "Leap Therapeutics, Inc.", "created": "March 31st, 2017", "published": true, "pretty": null, "uri": "/contracts/7jhEwTJL1PY", "title": "FIRST AMENDMENT TO LEASE", "group_id": "7jhEwTJL1PY", "group_samples": [{"label": "Lease (Leap Therapeutics, Inc.)", "uri": "/contracts/7jhEwTJL1PY", "published": true}], "group_size": 1, "tags": [{"name": "Lease", "type": "category", "uri": "/contracts/tagged/lease"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "Leap Therapeutics, Inc., a Delaware corporation (the \u201cCompany\u201d), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [\u00b7] or its registered assigns (the \u201cHolder\u201d), is entitled, subject to the terms set forth below, to purchase from the Company up to a total of [\u00b7] shares of common stock, $0.001 par value per share (the \u201cCommon Stock\u201d), of the Company (each such share, a \u201cWarrant Share\u201d and all such shares, the \u201cWarrant Shares\u201d) at an exercise price per share equal to $0.5335 (the \u201cExercise Price\u201d), in each case as adjusted from time to time as provided in Section 9, upon surrender of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the \u201cWarrant\u201d) at any time and from time to time on or after the Original Issue Date and on or prior to 5:00 p.m. (New York City Time) on the tenth anniversary of the Original Issue Date (the \u201cTerminat", "id": "7lKCtmKNP4E", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000110465925098082/tm2528058d2_ex4-1.htm", "category_name": "Security Agreement", "company_name": "Leap Therapeutics, Inc.", "created": "October 9th, 2025", "published": true, "pretty": null, "uri": "/contracts/7lKCtmKNP4E", "title": "FORM OF WARRANT TO PURCHASE COMMON STOCK", "group_id": "7lKCtmKNP4E", "group_samples": [{"label": "Security Agreement (Leap Therapeutics, Inc.)", "uri": "/contracts/7lKCtmKNP4E", "published": true}], "group_size": 1, "tags": [{"name": "Security Agreement", "type": "category", "uri": "/contracts/tagged/security-agreement"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This Consent to Assignment and Assumption of Lease (this \u201cAgreement\u201d) is made as of the 19th day of December, 2016 by and among Bulfinch Square Limited Partnership, a Massachusetts limited partnership (\u201cLandlord\u201d), HealthCare Ventures LLC, a Delaware limited liability company (\u201cTenant\u201d) and Leap Therapeutics, Inc., a Delaware corporation (\u201cAssignee\u201d).", "id": "9zquIW6v8rS", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000104746917002262/a2231451zex-10_29.htm", "category_name": "Consent to Assignment and Assumption of Lease", "company_name": "Leap Therapeutics, Inc.", "created": "March 31st, 2017", "published": true, "pretty": null, "uri": "/contracts/9zquIW6v8rS", "title": "CONSENT TO ASSIGNMENT AND ASSUMPTION OF LEASE", "group_id": "9zquIW6v8rS", "group_samples": [{"label": "Consent to Assignment and Assumption of Lease (Leap Therapeutics, Inc.)", "uri": "/contracts/9zquIW6v8rS", "published": true}], "group_size": 1, "tags": [{"name": "Consent to Assignment and Assumption of Lease", "type": "category", "uri": "/contracts/tagged/consent-to-assignment-and-assumption-of-lease"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "This Executive Employment Agreement (\u201cAgreement\u201d) is made and entered into as of this 11th day of November, 2025 (the \u201cEffective Date\u201d), by and between Leap Therapeutics, Inc., a Delaware corporation (the \u201cCompany\u201d), and William McEvoy (hereinafter, the \u201cExecutive\u201d).", "id": "a0Av0qQAaSB", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000110465925109820/tm2530735d1_ex10-3.htm", "category_name": "Executive Employment Agreement", "company_name": "Leap Therapeutics, Inc.", "created": "November 12th, 2025", "published": true, "pretty": null, "uri": "/contracts/a0Av0qQAaSB", "title": "EXECUTIVE EMPLOYMENT AGREEMENT", "group_id": "a0Av0qQAaSB", "group_samples": [{"label": "Executive Employment Agreement (Leap Therapeutics, Inc.)", "uri": "/contracts/a0Av0qQAaSB", "published": true}], "group_size": 1, "tags": [{"name": "Executive Employment Agreement", "type": "category", "uri": "/contracts/tagged/executive-employment-agreement"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "This Amendment to Lease (this \u201cAmendment\u201d) is made as of June 30, 2015 by and between BULFINCH SQUARE LIMITED PARTNERSHIP, a Massachusetts limited partnership (\u201cLandlord\u201d) and Healthcare Ventures, LLC a Delaware limited liability company \u201cTenant\u201d).", "id": "a0kVHzbriPm", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000104746917002262/a2231451zex-10_27.htm", "category_name": "Lease", "company_name": "Leap Therapeutics, Inc.", "created": "March 31st, 2017", "published": true, "pretty": null, "uri": "/contracts/a0kVHzbriPm", "title": "AMENDMENT TO LEASE", "group_id": "a0kVHzbriPm", "group_samples": [{"label": "Lease (Leap Therapeutics, Inc.)", "uri": "/contracts/a0kVHzbriPm", "published": true}], "group_size": 1, "tags": [{"name": "Lease", "type": "category", "uri": "/contracts/tagged/lease"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "THIS COLLABORATION AGREEMENT (the \u201cAgreement\u201d) is made effective as of April 2, 2024 (the \u201cRestatement Date\u201d), and amends and restates the Collaboration Agreement (the \u201cOriginal Agreement\u201d) dated August 10, 2020 (the \u201cEffective Date\u201d), by and between Adimab, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (\u201cAdimab\u201d), and Leap Therapeutics, Inc., 47 Thorndike Street, Suite Bl, Cambridge, MA 02141, which acquired Flame Biosciences, Inc., 555 Madison Ave., Suite 1201, New York, NY 10022 on January 17, 2023 (\u201cLeap\u201d).", "id": "b8BT2sZJ2e3", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000141057824001284/lptx-20240630xex10d2.htm", "category_name": "Collaboration Agreement", "company_name": "Leap Therapeutics, Inc.", "created": "August 12th, 2024", "published": true, "pretty": null, "uri": "/contracts/b8BT2sZJ2e3", "title": "FIRST AMENDED AND RESTATED COLLABORATION AGREEMENT", "group_id": "b8BT2sZJ2e3", "group_samples": [{"label": "Collaboration Agreement (Leap Therapeutics, Inc.)", "uri": "/contracts/b8BT2sZJ2e3", "published": true}], "group_size": 1, "tags": [{"name": "Collaboration Agreement", "type": "category", "uri": "/contracts/tagged/collaboration-agreement"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "THIS ASSET PURCHASE AGREEMENT (this \u201cAgreement\u201d), dated as of August 17, 2026, is entered into by and among MORIA MINING, LLC, a Delaware limited liability company (\u201cSeller\u201d), and WINKLEVOSS TREASURY INVESTMENTS, LLC, a Delaware limited liability company and an affiliate of Seller (\u201cWTI\u201d and together with Seller, \u201cSeller Parties\u201d), CYPHERPUNK MINING LLC, a Delaware limited liability company (\u201cBuyer\u201d), and CYPHERPUNK TECHNOLOGIES INC., a Delaware corporation and the sole member of Buyer (\u201cParent\u201d and together with Buyer, \u201cBuyer Parties\u201d). Each of Seller, WTI, Buyer and Parent is referred to herein as a \u201cParty\u201d and collectively as the \u201cParties.\u201d", "id": "bM6CpqwgbK2", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000110465926098120/tm2623453d1_ex1-1.htm", "category_name": "Asset Purchase Agreement", "company_name": "Cypherpunk Technologies Inc.", "created": "August 18th, 2026", "published": true, "pretty": null, "uri": "/contracts/bM6CpqwgbK2", "title": "ASSET PURCHASE AGREEMENT by and among CYPHERPUNK MINING LLC, CYPHERPUNK TECHNOLOGIES INC., MORIA MINING, LLC, and WINKLEVOSS TREASURY INVESTMENTS, LLC dated as of August 17, 2026", "group_id": "bM6CpqwgbK2", "group_samples": [{"label": "Asset Purchase Agreement (Cypherpunk Technologies Inc.)", "uri": "/contracts/bM6CpqwgbK2", "published": true}], "group_size": 1, "tags": [{"name": "Asset Purchase Agreement", "type": "category", "uri": "/contracts/tagged/asset-purchase-agreement"}, {"name": "Cypherpunk Technologies Inc.", "type": "company", "uri": "/company/1509745/cypherpunk-technologies-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This RESTRICTED STOCK UNIT GRANT AGREEMENT (the \u201cAgreement\u201d), dated as of December 23rd, 2025 (the \u201cDate of Grant\u201d), is delivered by Cypherpunk Technologies Inc. (formerly known as Leap Therapeutics, Inc.) (the \u201cCompany\u201d) to CoinXit Ltd (the \u201cParticipant\u201d).", "id": "bj4Qs25FhUb", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000110465925125224/tm2534480d1_ex10-1.htm", "category_name": "Restricted Stock Unit Grant Agreement", "company_name": "Cypherpunk Technologies Inc.", "created": "December 30th, 2025", "published": true, "pretty": null, "uri": "/contracts/bj4Qs25FhUb", "title": "RESTRICTED STOCK UNIT GRANT AGREEMENT", "group_id": "bj4Qs25FhUb", "group_samples": [{"label": "Restricted Stock Unit Grant Agreement (Cypherpunk Technologies Inc.)", "uri": "/contracts/bj4Qs25FhUb", "published": true}], "group_size": 1, "tags": [{"name": "Restricted Stock Unit Grant Agreement", "type": "category", "uri": "/contracts/tagged/restricted-stock-unit-grant-agreement"}, {"name": "Cypherpunk Technologies Inc.", "type": "company", "uri": "/company/1509745/cypherpunk-technologies-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "This Letter Agreement (\u201cLetter Agreement\u201d) is entered into as of January 23, 2017, by and among Leap Therapeutics, Inc., a Delaware corporation (\u201cLeap\u201d), Leap Shareholder Royalty Vehicle, LLC, a Delaware limited liability company (\u201cLeap SRV\u201d), HealthCare Ventures VIII, L.P., a Delaware limited partnership (\u201cHCV VIII\u201d), HealthCare Ventures IX, L.P., a Delaware limited partnership (\u201cHCV IX\u201d), HealthCare Strategic Fund, L.P., a Delaware limited partnership (\u201cHCV Strategic\u201d), and Eli Lilly and Company, an Indiana corporation (\u201cLilly\u201d and, together with HCV VIII, HCV IX and HCV Strategic, the \u201cInitial Members\u201d).", "id": "ciWUM14KauD", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000110465917004145/a17-3113_2ex10d2.htm", "category_name": "Letter Agreement", "company_name": "Leap Therapeutics, Inc.", "created": "January 26th, 2017", "published": true, "pretty": null, "uri": "/contracts/ciWUM14KauD", "title": "LETTER AGREEMENT", "group_id": "ciWUM14KauD", "group_samples": [{"label": "Letter Agreement (Leap Therapeutics, Inc.)", "uri": "/contracts/ciWUM14KauD", "published": true}], "group_size": 1, "tags": [{"name": "Letter Agreement", "type": "category", "uri": "/contracts/tagged/letter-agreement"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Amendment No. 1 to Registration Rights Agreement (this \u201cAmendment\u201d) is made and entered into as of August 17, 2026, by and between Cypherpunk Technologies Inc., a Delaware corporation (the \u201cCompany\u201d), and Winklevoss Treasury Investments, LLC (\u201cWTI\u201d). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Registration Rights Agreement (as defined below).", "id": "ciXh7GNDqeK", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000110465926098120/tm2623453d1_ex10-1.htm", "category_name": "Registration Rights Agreement", "company_name": "Cypherpunk Technologies Inc.", "created": "August 18th, 2026", "published": true, "pretty": null, "uri": "/contracts/ciXh7GNDqeK", "title": "FIRST AMENDMENT TO REGISTRATION RIGHTS AGREEMENT", "group_id": "ciXh7GNDqeK", "group_samples": [{"label": "Registration Rights Agreement (Cypherpunk Technologies Inc.)", "uri": "/contracts/ciXh7GNDqeK", "published": true}], "group_size": 1, "tags": [{"name": "Registration Rights Agreement", "type": "category", "uri": "/contracts/tagged/registration-rights-agreement"}, {"name": "Cypherpunk Technologies Inc.", "type": "company", "uri": "/company/1509745/cypherpunk-technologies-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This is a First Amendment to Lease dated as of August 17, 2021 by and between Bulfinch Square Limited Partnership, a Massachusetts limited partnership (\u201cLandlord\u201d) and Leap Therapeutics, Inc., a Delaware corporation (\u201cTenant\u201d).", "id": "dIklBCBekGv", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000110465921137410/lptx-20210930xex10d1.htm", "category_name": "Lease", "company_name": "Leap Therapeutics, Inc.", "created": "November 12th, 2021", "published": true, "pretty": null, "uri": "/contracts/dIklBCBekGv", "title": "FIRST AMENDMENT TO LEASE", "group_id": "dIklBCBekGv", "group_samples": [{"label": "Lease (Leap Therapeutics, Inc.)", "uri": "/contracts/dIklBCBekGv", "published": true}], "group_size": 1, "tags": [{"name": "Lease", "type": "category", "uri": "/contracts/tagged/lease"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "Leap Therapeutics, Inc., a Delaware corporation (the \u201cCompany\u201d), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the \u201cUnderwriters\u201d), an aggregate of (i) 6,571,428 shares (the \u201cFirm Shares\u201d) of its Common Stock, par value $0.001 per share (the \u201cCommon Stock\u201d) and (ii) warrants to purchase up to an aggregate of 6,571,428 shares of Common Stock on the terms and conditions set forth in the form of warrant attached as Exhibit A hereto (the \u201cFirm Warrants,\u201d and together with the Firm Shares, the \u201cFirm Securities\u201d). All of the Firm Securities are to be issued and sold by the Company. The respective amounts of the Firm Securities to be purchased by each of the several Underwriters are set forth on Schedule I hereto. In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional (i) 985,714 shares", "id": "deDdAz3bbrL", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000110465919005171/a19-3627_3ex1d1.htm", "category_name": "Underwriting Agreement", "company_name": "Leap Therapeutics, Inc.", "created": "February 1st, 2019", "published": true, "pretty": null, "uri": "/contracts/deDdAz3bbrL", "title": "And Warrants to Purchase up to 6,571,428 Shares of Common Stock UNDERWRITING AGREEMENT", "group_id": "deDdAz3bbrL", "group_samples": [{"label": "Underwriting Agreement (Leap Therapeutics, Inc.)", "uri": "/contracts/deDdAz3bbrL", "published": true}], "group_size": 1, "tags": [{"name": "Underwriting Agreement", "type": "category", "uri": "/contracts/tagged/underwriting-agreement"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "THIS LEAD INVESTOR AGREEMENT (this \u201cAgreement\u201d) is made and entered into as of October 6, 2025 (the \u201cEffective Date\u201d) by and among Leap Therapeutics, Inc., a Delaware corporation (the \u201cCompany\u201d) and Winklevoss Treasury Investments, LLC (the \u201cLead Investor\u201d). The Company and the Lead Investor are collectively referred to herein as the \u201cParties\u201d and each, a \u201cParty\u201d.", "id": "dfhXf0nfZoZ", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000110465925098082/tm2528058d2_ex10-3.htm", "category_name": "Lead Investor Agreement", "company_name": "Leap Therapeutics, Inc.", "created": "October 9th, 2025", "published": true, "pretty": null, "uri": "/contracts/dfhXf0nfZoZ", "title": "LEAD INVESTOR AGREEMENT", "group_id": "dfhXf0nfZoZ", "group_samples": [{"label": "Lead Investor Agreement (Leap Therapeutics, Inc.)", "uri": "/contracts/dfhXf0nfZoZ", "published": true}], "group_size": 1, "tags": [{"name": "Lead Investor Agreement", "type": "category", "uri": "/contracts/tagged/lead-investor-agreement"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "THIS AMENDED AND RESTATED STOCKHOLDERS\u2019 AGREEMENT, dated this 10th day of December, 2015 (this \u201cAgreement\u201d), is entered into by and among Leap Therapeutics, Inc., a Delaware corporation, f/k/a Dekkun Corporation and HealthCare Pharmaceuticals, Inc. (the \u201cCorporation\u201d), and (i) the holders of Series A Convertible Preferred Stock, par value $.001 per share, of the Corporation (the \u201cSeries A Preferred Stock\u201d) listed on Schedule 1 hereto (each individually a \u201cSeries A Holder\u201d and, collectively, the \u201cSeries A Holders\u201d), (ii) those holders of Series B Convertible Redeemable Preferred Stock, par value $.001 per share, of the Corporation (the \u201cSeries B Preferred Stock\u201d) listed on Schedule 2 hereto (each individually, a \u201cSeries B Holder\u201d and, collectively, the \u201cSeries B Holders\u201d), and (iii) the holder of Series C Convertible Preferred Stock, par value $.001 per share, of the Corporation (the \u201cSeries C Preferred Stock\u201d) listed on Schedule 3 hereto (each individually a \u201cSeries C Holder\u201d and, coll", "id": "eLuKSbjMTJz", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000104746916015711/a2229626zex-4_2.htm", "category_name": "Stockholders Agreement", "company_name": "Leap Therapeutics, Inc.", "created": "September 26th, 2016", "published": true, "pretty": null, "uri": "/contracts/eLuKSbjMTJz", "title": "AMENDED AND RESTATED STOCKHOLDERS\u2019 AGREEMENT", "group_id": "eLuKSbjMTJz", "group_samples": [{"label": "Stockholders Agreement (Leap Therapeutics, Inc.)", "uri": "/contracts/eLuKSbjMTJz", "published": true}], "group_size": 1, "tags": [{"name": "Stockholders Agreement", "type": "category", "uri": "/contracts/tagged/stockholders-agreement"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the \u201cWarrant\u201d) certifies that, for value received, __________ or its assigns (the \u201cHolder\u201d) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the \u201cInitial Exercise Date\u201d) until this Warrant is exercised in full (the \u201cTermination Date\u201d), to subscribe for and purchase from Leap Therapeutics, Inc., a Delaware corporation (the \u201cCompany\u201d), up to [\u25cf] shares of common stock, par value $0.001 per share (the \u201cCommon Stock\u201d and such Common Stock underlying this Warrant, subject to adjustment hereunder, the \u201cWarrant Shares\u201d) of the Company. The purchase price of one share of Common Stock underlying this Warrant shall be equal to the Exercise Price set forth in Section 2(b) below.", "id": "eWuE22FP9Vg", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000110465925098082/tm2528058d2_ex4-2.htm", "category_name": "Security Agreement", "company_name": "Leap Therapeutics, Inc.", "created": "October 9th, 2025", "published": true, "pretty": null, "uri": "/contracts/eWuE22FP9Vg", "title": "FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT LEAP THERAPEUTICS, INC.", "group_id": "eWuE22FP9Vg", "group_samples": [{"label": "Security Agreement (Leap Therapeutics, Inc.)", "uri": "/contracts/eWuE22FP9Vg", "published": true}], "group_size": 1, "tags": [{"name": "Security Agreement", "type": "category", "uri": "/contracts/tagged/security-agreement"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This First Amendment (the \u201cAmendment\u201d) to Executive Employment Agreement is made and entered into as of this 15th day of April, 2021 (the \u201cAmendment Date\u201d), by and between Leap Therapeutics, Inc., a Delaware corporation (the \u201cCompany\u201d), and Cynthia Sirard (hereinafter, the \u201cExecutive\u201d).", "id": "epFuKS2XsBq", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000110465921104593/lptx-20210630xex10d1.htm", "category_name": "Executive Employment Agreement", "company_name": "Leap Therapeutics, Inc.", "created": "August 13th, 2021", "published": true, "pretty": null, "uri": "/contracts/epFuKS2XsBq", "title": "FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT", "group_id": "epFuKS2XsBq", "group_samples": [{"label": "Executive Employment Agreement (Leap Therapeutics, Inc.)", "uri": "/contracts/epFuKS2XsBq", "published": true}], "group_size": 1, "tags": [{"name": "Executive Employment Agreement", "type": "category", "uri": "/contracts/tagged/executive-employment-agreement"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "This is a Fifth Amendment to Lease dated as of July 1, 2025 by and between Bulfinch Square Limited Partnership, a Massachusetts limited partnership (\u201cLandlord\u201d) and Leap Therapeutics, Inc., a Delaware corporation (\u201cTenant\u201d).", "id": "fV8bcigr3Tf", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000141057825001774/lptx-20250630xex10d1.htm", "category_name": "Lease", "company_name": "Leap Therapeutics, Inc.", "created": "August 14th, 2025", "published": true, "pretty": null, "uri": "/contracts/fV8bcigr3Tf", "title": "FIFTH AMENDMENT TO LEASE", "group_id": "fV8bcigr3Tf", "group_samples": [{"label": "Lease (Leap Therapeutics, Inc.)", "uri": "/contracts/fV8bcigr3Tf", "published": true}], "group_size": 1, "tags": [{"name": "Lease", "type": "category", "uri": "/contracts/tagged/lease"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "THIS AMENDMENT NO. 2, dated as of , 2016 (the \u201cAmendment\u201d), to that certain Warrant to Purchase Preferred A Shares of Macrocure Ltd., an Israeli company (the \u201cCompany\u201d), dated May 3, 2012, as amended by Amendment No. 1 thereto, dated as of July 22, 2013 (as so amended, the \u201cWarrant\u201d), is entered into by and among the Company, the individual or entity listed on the signature page hereto, who/which is the holder of the Warrant (the \u201cHolder\u201d), and Leap Therapeutics, Inc., a company organized under the laws of the State of Delaware (the \u201cAcquirer\u201d). Capitalized terms used herein and not otherwise defined shall have the meaning ascribed to them in the Warrant.", "id": "fjkwJ3ZUfMG", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000104746916015711/a2229626zex-4_4.htm", "category_name": "Warrant", "company_name": "Leap Therapeutics, Inc.", "created": "September 26th, 2016", "published": true, "pretty": null, "uri": "/contracts/fjkwJ3ZUfMG", "title": "AMENDMENT NO. 2 TO WARRANT", "group_id": "fjkwJ3ZUfMG", "group_samples": [{"label": "Warrant (Leap Therapeutics, Inc.)", "uri": "/contracts/fjkwJ3ZUfMG", "published": true}], "group_size": 1, "tags": [{"name": "Warrant", "type": "category", "uri": "/contracts/tagged/warrant"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}]}, {"intro": "THIS AMENDMENT NO. 2, dated as of January 23, 2017 (the \u201cAmendment\u201d), to that certain Warrant to Purchase Preferred A Shares of Macrocure Ltd., an Israeli company (the \u201cCompany\u201d), dated May 3, 2012, as amended by Amendment No. 1 thereto, dated as of July 22, 2013 (as so amended, the \u201cWarrant\u201d), is entered into by and among the Company, the individual or entity listed on the signature page hereto, who/which is the holder of the Warrant (the \u201cHolder\u201d), and Leap Therapeutics, Inc., a company organized under the laws of the State of Delaware (the \u201cAcquirer\u201d). Capitalized terms used herein and not otherwise defined shall have the meaning ascribed to them in the Warrant.", "id": "fpgJHIZYbSS", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000104746917002262/a2231451zex-4_4.htm", "category_name": "Warrant", "company_name": "Leap Therapeutics, Inc.", "created": "March 31st, 2017", "published": true, "pretty": null, "uri": "/contracts/fpgJHIZYbSS", "title": "AMENDMENT NO. 2 TO WARRANT", "group_id": "fpgJHIZYbSS", "group_samples": [{"label": "Warrant (Leap Therapeutics, Inc.)", "uri": "/contracts/fpgJHIZYbSS", "published": true}], "group_size": 1, "tags": [{"name": "Warrant", "type": "category", "uri": "/contracts/tagged/warrant"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "Reference is hereby made to (i) that certain Exclusive Option and License Agreement, dated as of January 3, 2020 (the \u201cOption and License Agreement\u201d), by and between Leap Therapeutics, Inc., a Delaware corporation (\u201cLeap\u201d), and BeiGene, Ltd., a Cayman Island exempted company incorporated with limited liability (\u201cBeiGene\u201d), (ii) that certain Clinical Manufacturing and Supply Agreement, dated as of April 23, 2020, by and between Leap and BeiGene, as amended, modified or supplemented from time to time prior to the date hereof (the \u201cSupply Agreement\u201d), (iii) that certain Clinical Quality Agreement, dated as of May 3, 2020, by and between Leap and BeiGene, as amended, modified or supplemented from time to time prior to the date hereof (the \u201cQuality Agreement\u201d), and (iv) that certain First Amended and Restated Pharmacovigilance Agreement, dated as of October 12, 2022, by and between Leap and BeiGene, as amended, modified or supplemented from time to time prior to the date hereof (the \u201cPharma", "id": "gn92ctzerUo", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000110465923033314/tm239782d1_ex10-1.htm", "category_name": "Termination of Option and License; Continued Clinical Collaboration", "company_name": "Leap Therapeutics, Inc.", "created": "March 16th, 2023", "published": true, "pretty": null, "uri": "/contracts/gn92ctzerUo", "title": "March 16, 2023", "group_id": "gn92ctzerUo", "group_samples": [{"label": "Termination of Option and License; Continued Clinical Collaboration (Leap Therapeutics, Inc.)", "uri": "/contracts/gn92ctzerUo", "published": true}], "group_size": 1, "tags": [{"name": "Termination of Option and License; Continued Clinical Collaboration", "type": "category", "uri": "/contracts/tagged/termination-of-option-and-license-continued-clinical-collaboration"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Securities Purchase Agreement (this \u201cAgreement\u201d) is dated as of April 10, 2024, among Leap Therapeutics, Inc., a Delaware corporation (the \u201cCompany\u201d), and each purchaser whose name is set forth on Exhibit A (each a \u201cPurchaser\u201d and collectively the \u201cPurchasers\u201d).", "id": "jG6IBDImewX", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000110465924046108/tm2411534d1_ex10-1.htm", "category_name": "Securities Purchase Agreement", "company_name": "Leap Therapeutics, Inc.", "created": "April 11th, 2024", "published": true, "pretty": null, "uri": "/contracts/jG6IBDImewX", "title": "SECURITIES PURCHASE AGREEMENT", "group_id": "jG6IBDImewX", "group_samples": [{"label": "Securities Purchase Agreement (Leap Therapeutics, Inc.)", "uri": "/contracts/jG6IBDImewX", "published": true}], "group_size": 1, "tags": [{"name": "Securities Purchase Agreement", "type": "category", "uri": "/contracts/tagged/securities-purchase-agreement"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "This Consulting Agreement (the \u201cAgreement\u201d) is made as of the Effective Date set forth above by and between Leap Therapeutics, Inc. (\u201cClient\u201d) and the consultant named on the signature page hereto (\u201cConsultant\u201d).", "id": "jVALPrKDch8", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000110465925109820/tm2530735d1_ex10-1.htm", "category_name": "Consulting Agreement", "company_name": "Leap Therapeutics, Inc.", "created": "November 12th, 2025", "published": true, "pretty": null, "uri": "/contracts/jVALPrKDch8", "title": "LEAP THERAPEUTICS, INC. CONSULTING AGREEMENT Effective Date: November 11, 2025", "group_id": "jVALPrKDch8", "group_samples": [{"label": "Consulting Agreement (Leap Therapeutics, Inc.)", "uri": "/contracts/jVALPrKDch8", "published": true}], "group_size": 1, "tags": [{"name": "Consulting Agreement", "type": "category", "uri": "/contracts/tagged/consulting-agreement"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "THIS VOTING AGREEMENT is made as of January 3, 2020 (the \u201cAgreement\u201d), by and among Leap Therapeutics, Inc., a Delaware corporation (the \u201cCompany\u201d), and [INSERT NAME OF STOCKHOLDER] (the \u201cStockholder\u201d). Capitalized terms used in this Agreement without definition shall have the respective meanings ascribed to such terms in the Purchase Agreement (as defined below).", "id": "kAKtRu3cVZq", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000110465920002039/tm201393d1_ex10-3.htm", "category_name": "Voting Agreement", "company_name": "Leap Therapeutics, Inc.", "created": "January 7th, 2020", "published": true, "pretty": null, "uri": "/contracts/kAKtRu3cVZq", "title": "VOTING AGREEMENT", "group_id": "kAKtRu3cVZq", "group_samples": [{"label": "Voting Agreement (Leap Therapeutics, Inc.)", "uri": "/contracts/kAKtRu3cVZq", "published": true}], "group_size": 1, "tags": [{"name": "Voting Agreement", "type": "category", "uri": "/contracts/tagged/voting-agreement"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "This Subscription Agreement (this \u201cAgreement\u201d) is made as of January 23, 2017, by and between Leap Therapeutics, Inc., a Delaware company (the \u201cCompany\u201d), and HealthCare Ventures IX, L.P., a Delaware limited partnership (the \u201cSubscriber\u201d).", "id": "lBwmhPWOQg9", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000110465917004145/a17-3113_2ex10d4.htm", "category_name": "Subscription Agreement", "company_name": "Leap Therapeutics, Inc.", "created": "January 26th, 2017", "published": true, "pretty": null, "uri": "/contracts/lBwmhPWOQg9", "title": "SUBSCRIPTION AGREEMENT", "group_id": "lBwmhPWOQg9", "group_samples": [{"label": "Subscription Agreement (Leap Therapeutics, Inc.)", "uri": "/contracts/lBwmhPWOQg9", "published": true}], "group_size": 1, "tags": [{"name": "Subscription Agreement", "type": "category", "uri": "/contracts/tagged/subscription-agreement"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "THIS COLLABORATION AGREEMENT (the \u201cAgreement\u201d) is made effective as of August 10, 2020 (the \u201cEffective Date\u201d), by and between Adimab, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (\u201cAdimab\u201d), and Flame Biosciences, Inc., 555 Madison Ave., Suite 1201, New York, NY 10022 (\u201cFlame\u201d).", "id": "lsypqMsFK4s", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000110465923060153/lptx-20230331xex10d2.htm", "category_name": "Collaboration Agreement", "company_name": "Leap Therapeutics, Inc.", "created": "May 15th, 2023", "published": true, "pretty": null, "uri": "/contracts/lsypqMsFK4s", "title": "COLLABORATION AGREEMENT", "group_id": "lsypqMsFK4s", "group_samples": [{"label": "Collaboration Agreement (Leap Therapeutics, Inc.)", "uri": "/contracts/lsypqMsFK4s", "published": true}], "group_size": 1, "tags": [{"name": "Collaboration Agreement", "type": "category", "uri": "/contracts/tagged/collaboration-agreement"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE \u201cSECURITIES ACT\u201d) OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH TRANSACTION UNDER APPLICABLE SECURITIES LAWS OR UNLESS OFFERED, SOLD, PLEDGED, HYPOTHECATED OR TRANSFERRED PURSUANT TO AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THOSE LAWS. THE COMPANY SHALL BE ENTITLED TO REQUIRE AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.", "id": "qsAt9kaI6c", "source_url": "https://www.sec.gov/Archives/edgar/data/1509745/000110465923060153/lptx-20230331xex4d1.htm", "category_name": "Stock Warrant", "company_name": "Leap Therapeutics, Inc.", "created": "May 15th, 2023", "published": true, "pretty": null, "uri": "/contracts/qsAt9kaI6c", "title": "Contract", "group_id": "qsAt9kaI6c", "group_samples": [{"label": "Stock Warrant (Leap Therapeutics, Inc.)", "uri": "/contracts/qsAt9kaI6c", "published": true}], "group_size": 1, "tags": [{"name": "Stock Warrant", "type": "category", "uri": "/contracts/tagged/stock-warrant"}, {"name": "Leap Therapeutics, Inc.", "type": "company", "uri": "/company/1509745/leap-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}], "next_curs": "", "cursor": "CjEKEAoKZ3JvdXBfc2l6ZRICCAEKGQoIZ3JvdXBfaWQSDRoLMjE4WU5jV0lTTmEYACAB"}}